Werewolf Therapeutics Inc HOWL:NASDAQ

RT Quote | USD
Last | 04/18/24 EDT
5.87quote price arrow up+0.03 (+0.51%)
Volume
116,843
52 week range
1.57 - 8.19
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close5.84
  • 52 Week High8.19
  • 52 Week High Date02/26/24
  • 52 Week Low1.57
  • 52 Week Low Date10/24/23

Key Stats

  • Market Cap254.449M
  • Shares Out43.35M
  • 10 Day Average Volume0.24M
  • Dividend-
  • Dividend Yield-
  • Beta0.71
  • YTD % Change52.07

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close5.84
  • 52 Week High8.19
  • 52 Week High Date02/26/24
  • 52 Week Low1.57
  • 52 Week Low Date10/24/23
  • Market Cap254.449M
  • Shares Out43.35M
  • 10 Day Average Volume0.24M
  • Dividend-
  • Dividend Yield-
  • Beta0.71
  • YTD % Change52.07

RATIOS/PROFITABILITY

  • EPS (TTM)-1.05
  • P/E (TTM)-5.60
  • Fwd P/E (NTM)-4.41
  • EBITDA (TTM)-38.739M
  • ROE (TTM)-31.98%
  • Revenue (TTM)19.943M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-187.37%
  • Debt To Equity (MRQ)35.31%

EVENTS

  • Earnings Date05/20/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Werewolf Therapeutics Inc

 

Profile

MORE
Werewolf Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain...
Luke Evnin Ph.D.
Independent Chairman of the Board
Daniel Hicklin Ph.D.
President, Chief Executive Officer, Director
Reid Leonard Ph.D.
Chief Operating Officer
Timothy Trost CPA
Chief Financial Officer, Treasurer
Chulani Karunatilake Ph.D.
Chief Technology Officer
Address
200 Talcott Avenue, 2Nd Floor
Watertown, MA
02472
United States

Top Peers

SYMBOLLASTCHG%CHG
BLUE
bluebird bio Inc
0.953-0.0103-1.0692%
CAPR
Capricor Therapeutics Inc
5.05-0.50-9.01%
ZVRA
Zevra Therapeutics Inc
4.50-0.14-3.02%
PRQR
ProQR Therapeutics NV
1.86-0.04-2.11%
CLLS
Cellectis SA
2.47+0.01+0.41%